H
Hemarina
Develops marine oxygen carriers for industrial and therapeutic applications
About Hemarina
Hemarina operates in the biotechnology sector, focusing on the development of marine-based oxygen carriers for medical applications. The company primarily serves healthcare providers and research institutions involved in organ transplantation and preservation. Hemarina's business model revolves around the commercialization of its proprietary oxygen carrier products, such as HEMO2life, which are designed to improve the preservation and functionality of organs during transplantation. By enhancing oxygenation, these products aim to reduce ischemia-reperfusion injuries and improve graft outcomes. Revenue is generated through the sale of these specialized products to hospitals and research facilities. The market for Hemarina's offerings includes organ transplant centers and biopharmaceutical companies seeking advanced solutions for organ preservation and transplantation. The company's unique approach leverages marine biology to address critical challenges in organ transplantation, positioning it as a key player in this niche market.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2007
- Headquarters
- Morlaix, France
- Employees
- 17
- Open positions
- None listed
- Dealroom signal
- 70.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Intellectual Property, Biotechnology, Marine, Neurology, Biotech and Pharma, Blue Economy, Blue Biotechnology, Hard Tech, Horizon Europe, observatoire industrial tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Mar 2017 | $8.8M | $35M | Business Angels Des Grandes Ecoles · Armor Angels · Crédit Mutuel Equity · Force 29 | ↗ |
| SERIES C✓Equity / VC | Mar 2014 | $4.4M | $18M | Finistere Angels · Armor Angels · Crédit Mutuel Equity · Business Angels Des Grandes Ecoles | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Hemarina is 2.2K monthly website visits, down 12% over the last three months. Hemarina's team declined 5.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Inserm Transfert Initiative
Finistere Ventures
Armor Angels
Arkea Capital
Finistere Angels
Force 29
Series B and later2 investors entered at this stage
Crédit Mutuel Equity
Business Angels Des Grandes Ecoles
Other known investors2 additional known investors
Agoranov
Crédit Mutuel Innovation
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hemarina on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hemarina’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.